Canaccord Genuity Assumes Coverage on Abraxas Petroleum (AXAS) at Buy; Bakken Development Plans in Focus After Portfolio Update
Get Alerts AXAS Hot Sheet
Price: $0.03 --0%
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity assumes coverage on Abraxas Petroleum (NASDAQ: AXAS) with a Buy. PT lowered to $6.
Canaccord analyst, John Gerdes, said, "Our conviction was strengthened by the recent project updates and rig acquisition. We remain encouraged by the company’s growing exposure to an oil-weighted production base. In our view, there is significant value embedded in the company’s oil plays that will be unlocked this year through the successful execution of its Bakken, Eagle Ford, Niobrara, and Permian projects."
For more ratings news on Abraxas Petroleum click here and for the rating history of Abraxas Petroleum click here.
Shares of Abraxas Petroleum closed at $4.13 yesterday.
Canaccord analyst, John Gerdes, said, "Our conviction was strengthened by the recent project updates and rig acquisition. We remain encouraged by the company’s growing exposure to an oil-weighted production base. In our view, there is significant value embedded in the company’s oil plays that will be unlocked this year through the successful execution of its Bakken, Eagle Ford, Niobrara, and Permian projects."
For more ratings news on Abraxas Petroleum click here and for the rating history of Abraxas Petroleum click here.
Shares of Abraxas Petroleum closed at $4.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- UBS Starts Schrodinger (SDGR) at Neutral
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Bakken FormationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share